→ Still recovering from the hammering it took on the failure of its Alzheimer’s drug, little vTv $VTVT is pushing out post hoc analysis on a tiny subgroup of patients in an effort to prove its drug isn’t worthless. A tiny group of 18 Alzheimer’s patients with diabetes demonstrated a 6.1 point benefit on ADAS-cog relative to the placebo group. They claimed that was statistically significant, though skeptics are likely to hoot.
→ Oyster Point has rolled out more data to support its case that its pair of nasal sprays can shake Allergan and Shire’s dominance in dry eye disease. All three doses of OC-01 notched statistically significant mean change in Schirmer’s score — a measure of tear production — compared to the vehicle control, as did OC-02 in a separate trial. The biotech will now shift gears to a Phase III program, set to launch in 2019 provided talks with regulators go well.
→ The AI experts at Xtalpi has landed an $46 million extension round to build out their algorithmic tools for drug discovery and predictions, with big support from China Life Healthcare Fund and participation from SIG and Yael Capital. They are calling the round a Series B-1, as it follows a $15 million raise in January backed by Sequoia China, Google and Tencent.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 33,900+ biopharma pros who read Endpoints News by email every day.Free Subscription